MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease by Hong-Ling Jia et al.
RESEARCH ARTICLE Open Access
MicroRNA expression profile in exosome
discriminates extremely severe infections from
mild infections for hand, foot and mouth disease
Hong-Ling Jia2†, Chun-Hui He1†, Zhuo-Ya Wang4, Yu-Fen Xu1, Gen-Quan Yin1, Li-Jia Mao1, Chao-Wu Liu3*
and Li Deng1*
Abstract
Background: Changes of miRNAs in exosome have been reported in different disease diagnosis and provided as
potential biomarkers. In this study, we compared microRNA profile in exosomes in 5 MHFMD and 5 ESHFMD as well
as in 5 healthy children.
Methods: Different expression of miRNAs in exosomes across all the three groups were screened using miRNA
microarray method. Further validated test was conducted through quantitative real-time PCR assays with 54
exosome samples (18 ESHFMD, 18 MHFMD, and 18 healthy control). The judgment accuracy was then estimated by
the receiver operating characteristic (ROC) curve analysis; and the specificity and sensitivity were evaluated by the
multiple logistic regression analysis.
Results: There were 11 different miRNAs in exosomes of MHFMD and ESHFMD compared to healthy children, of which
4 were up-regulated and 7 were down-regulated. Further validation indicated that the 4 significant differentially expressed
candidate miRNAs (miR-671-5p, miR-16-5p, miR-150-3p, and miR-4281) in exosome showed the same changes as in the
microarray analysis, and the expression level of three miRNAs (miR-671-5p, miR-16-5p, and miR-150-3p) were significantly
different between MHFMD or ESHFMD and the healthy controls. The accuracy of the test results were high with the under
curve (AUC) value range from 0.79 to 1.00. They also provided a specificity of 72%-100% and a sensitivity of 78%-100%,
which possessed ability to discriminate ESHFMD from MHFMD with the AUC value of 0.76-0.82.
Conclusions: This study indicated that the exosomal miRNA from patients with different condition of HFMD express
unique miRNA profiles. Exosomal miRNA expression profiles may provide supplemental biomarkers for diagnosing and
subtyping HFMD infections.
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Background
Hand, foot, and mouth disease (HFMD) is a common
acute viral illness which has been epidemic worldwide
[1-3]. The two major causative agents are known as hu-
man enterovirus 71 (EV71) [4] and coxsackievirus A16
(CVA16), which accounting for more than 70% of cases
in recent outbreaks [5]. Moreover, the effective and reli-
able tool for diagnosing of HFMD is not available [6,7].
The extremely severe HFMD (ESHFMD) mainly caused
by EV71 with severe neurologic clinical symptoms and sig-
nificant fatalities [8-10], that had caused serious public
health concerns. Many children with extremely severe
HFMD were died before making a definite diagnosis. Thus,
a rapid and reliable diagnostic method is essential for ap-
propriate treatment and prophylaxis.
Exosome represent a specific subtype of secreted mem-
brane vesicles that are approximately 30–100 nm in
size and are formed inside the secreting cells in endosomal
compartments called multivesicular bodies [11,12]. Secreted
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vesicles play an important role in normal physiological
processes, development, and conditions such as viral in-
fection [13-15] and are a possible source or pool of
novel biomarkers of many diseases [16-18]. Exosome
contain proteins, miRNAs, and mRNAs, and the exoso-
mal lipid bilayer protects this genetic information from
degradation. Moreover, miRNAs can be transferred by
an exosomal route and further exert gene silencing in
recipient cells [19,20], where they play an essential
regulatory role during development, with their levels
changing in different cell types and at different devel-
opmental stages [21,22]. Although the mechanistic
basis for alterations in miRNA, especially in the context
of cellular malfunction, is not well understood, such al-
terations play a pivotal role in pathological processes
and have recently been proposed as biomarkers for
brain neoplasms, degenerative diseases, autism, and
schizophrenia [23-25]. Changes in exosomal miRNAs
have been reported in patients diagnosed with Alzheimer’s
disease (AD), and miRNAs have been shown to provide
diagnostic biomarkers [26].
Here, we employed microarray methods to compare
the miRNAs of exosome from serum samples collected
from normal children and patients with mild HFMD
(MHFMD) and extremely severe HFMD (ESHFMD). We
focused on the miRNA profile of exosome and con-
firmed whether these changes could be used to discrim-
ination of specific condition for ESHFMD and MHFMD.
Methods
Serum sample preparation
Ethical approval was obtained for human sample collec-
tion from the Ethics Committees at Guangzhou Women
and Children’s Medical Center, and written informed
consent was obtained from all guardians. Blood samples
from five MHFMD and five ESHFMD children diagnosed
according to the Hand Foot and Mouth Disease Prevention
Control Guide (2008 edition) issued by the Ministry of
Health of China (http://www.moh.gov.cn/publicfiles/busi-
ness/htmlfiles/mohbgt/s9511/200805/34775.htm) were ran-
domly collected for 2-DE, and clinical symptoms and
laboratory testing (EV71 nucleic acid detection kit) con-
firmed that EV71 infection caused HFMD in all these cases.
In addition to meeting the above criteria, ESHFMD pa-
tients all had encephalitis and pulmonary haemorrhage,
required mechanical ventilation, and had other clinical
symptoms. They were confirmed to have no other dis-
ease after a systematic check in the hospital. Five blood
samples from healthy children were collected as con-
trols. To validate the miRNA microarray results, we
randomly collected blood samples of 18 ESHFMD pa-
tients and 18 MHFMD patients according to the diag-
nostic guidelines described above and subjected the
samples to real-time quantitative RT-PCR. Another 18
blood samples from healthy children were collected as
controls. Blood samples were separated by centrifuga-
tion at 1,000 × g for 10 min. Serum aliquots were col-
lected and stored at −80°C. The serum obtained was
further processed for exosome isolation.
ExoQuick precipitation of serum exosome
We isolated exosome from the sera of all participants by
using ExoQuick precipitation (System Biosciences Inc,
Mountain View, CA) following the manufacturer’s in-
structions [27,28].
Exosome characterization
Transmission electron microscopy (TEM)
The exosome extraction reagent was used to precipitate
the exosome from serum, which were then centrifuged
at 1,500 × g for 10 min at 4°C to remove the supernatant.
The exosome pellet was resuspended in 10 mM PBS in
four times the volume of serum. A copper mesh was
placed on a clean wax plate, and 100 μl of the exosome
suspension was added. After 4 min, the copper mesh
was removed and placed in 2% phosphotungstic acid for
5 min. The mesh was laid on the filter paper for air-
drying, and TEM was used to observe the morphological
features of the exosome.
Western blot analysis
The exosome pellet was dissolved in the protein lysis
buffer, and the protein concentration was determined
using a Bradford protein assay kit (Bio-Rad, USA). Sam-
ples were separated on a 1D SDS-PAGE gel before trans-
fer to a PVDF membrane. The membrane was incubated
with the TSG101, CD63, CD9, HSP90α and Flotillin pri-
mary antibodies at 4°C overnight, followed by incubation
with the corresponding secondary antibodies at room
temperature for 1 h. Specific protein bands were visual-
ized using the SuperSignal chemiluminescence system
(ECL, Pierce, USA) and imaged by autoradiography.
RNA extraction from exosome
RNA was extracted from the exosome pellets using TRI-
ZOL reagent according to the manufacturer’s protocol.
Briefly, 1.0 ml of TRIZOL reagent and 200 μl of chloro-
form were added to the sample, and the mixture was
vortexed for 60 s and allowed to stand at 25°C for
5 min. After the mixture was centrifuged at 10,000 × g
for 10 min at 4°C, the supernatant was transferred to a
fresh tube and 500 μl of isopropanol was added. After
incubation at −20°C overnight, the mixture was centri-
fuged at 10,000 × g for 10 min at 4°C to remove the
supernatant, and the RNA pellet was washed with 75%
ethanol. After ethanol removal by centrifugation at
10,000 × g for 10 min at 4°C, the RNA was air-dried for
5 min and then dissolved in 20 μl of RNase-free water.
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The purity of the isolated RNA was determined accord-
ing to the OD260/280 using a Nanodrop ND-1000 sys-
tem (Thermo Fisher Scientific).
Microarray analysis
Pooled exosome of serum from five healthy children, five
MHFMD and five ESHFMD patients were used for miRNA
microarray analysis. Total miRNA from these three pooled
samples was extracted as described above. Microarray
hybridization, data generation, and normalization were per-
formed by the Shanghai Biochip Corp. following standard
Agilent protocols. Human miRNA microarrays from
Agilent Technologies, which contain probes for 1,887
human miRNAs from the Sanger database v.18.0, were
used in this study. Visualization of microarray data was
performed using MeV 4.6 software (MultiExperiment
Viewer; http://www.tm4.org/mev.html). The microarray
data described herein have been deposited in the National
Center for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/), with acces-
sion number GSE52780. A miRNA was designated as
overexpressed if expression in one of the pooled samples
was >1.5-fold higher than that in another sample. In cases
where overexpression was determined for a differentially
expressed miRNA, miRNA with the maximum intensity
over 4 (log2 transformed intensity) in at least one of the
paired samples was considered.
Validation of real-time quantitative PCR
For testing of candidate miRNAs identified by microar-
rays, real-time quantitative PCR (qRT-PCR) was per-
formed using the Power SYBR Green PCR Master Mix
(Applied Biosystems) in an ABI 7500 Real-Time PCR
System (Applied Biosystems). The assays were per-
formed on 54 samples (18 Control, 18MHFMD and 18
ESHFMD) for four candidates (miR-16-5p, miR-15-3p,
mir-4281, and miR-671) that met the defined criteria.
Each reaction was performed in a 20 μl volume system
containing 5 μl of cDNA, 0.5 μl of each primer, 10 μl of
Power SYBR Green PCR Master Mix, and 4.0 μl of
RNase-free water. The PCR program consisted of de-
naturation at 95°C for 2 min, followed by 40 cycles each
of denaturation for 15 s at 95°C and annealing and exten-
sion for 30 s at 60°C. The miR-642a-3p expression level
was used as a stable endogenous control for normalization.
All assays were conducted in triplicate. miRNAs that
showed cycle threshold values above 35 in one of the 54
samples were excluded from additional statistical analysis.
Target prediction and enrichment information
The target genes of the candidate miRNAs were predicted
by TargetScan prediction software (http://www.targetscan.
org/). The Gene Ontology (GO) and Kyoto Encyclopedia
of Genes and Genomes (KEGG) database analyses were
conducted using a DAVID online analysis tool (http://
david.abcc.ncifcrf.gov/), in which we focused on the
Gene Ontology (GO) biological processes feature. For
each analysis, we used P < 0.05 as a cut-off.
Statistical analysis
For the qRT-PCR data, relative miRNA expression levels
were calculated by the comparative 2-△△Ct method as de-
scribed previously [29]. Statistical significance was deter-
mined using Student’s t-test. P < 0.05 was considered
statistically significant. Receiver operating characteristic
(ROC) curves were constructed to determine the specifi-
city and sensitivity of individual miRNAs as surrogate
biomarkers. Area under the ROC curve (AUC) was used
as an accuracy index for evaluating the diagnostic per-
formance of the selected miRNA panel. MedCalc (ver-
sion 10.4.7.0; MedCalc, Mariakerke, Belgium) software
was used to perform the ROC analysis.
Results
Exosome isolation and validation
Microvesicles isolated from sera of controls and MHFMD
and ESHFMD patients were assessed by TEM and western
blotting. TEM showed spherical structures approximately
30–100 nm in diameter, consistent with previously re-
ported characteristics of exosomes (Figure 1A). We fur-
ther confirmed that these microvesicles were exosome by
performing western blot analysis on lysates using anti-
bodies against five commonly used exosomal markers,
TSG101, CD63, CD9, HSP90α and Flotillin. Levels of
TSG101, CD63, CD9, HSP90α and Flotillin were strik-
ingly higher in the microvesicle fraction than in serum
(Figure 1B). These results confirmed the identification and
characterization of isolated microvesicles as exosomes.
Global exosome miRNA profiling from microarray analysis
To screen for candidate exosomal miRNAs from
MHFMD and ESHFMD patient serum samples, miRNA
microarrays were used to evaluate the three groups
(MHFMD, ESHFMD, and control). The microarray re-
sults identified various miRNAs that were differentially
regulated in the exosome of MHFMD and ESHFMD
samples relative to healthy controls, and a scatter plot
was generated (Figure 2A). Subsequently, we conducted
pairwise comparison of the results of the scatter plot
charts and found 36 miRNAs with significantly different
expression between MHFMD and the control, 68 miR-
NAs differentially expressed between ESHFMD and the
control, and 65 miRNAs differentially expressed be-
tween ESHFMD and MHFMD. Eleven miRNAs, that
are miR-671-5p, miR-4463, miR-144-3p, miR-4271,
miR-4433-3p, miR-19b-3p, miR-4428, miR-135a-3p,
miR-4281, miR-16-5p, and miR-150-3p, showed signifi-
cantly different expression across all three groups
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(Figure 2B), indicating a clear distinction between the
MHFMD, ESHFMD, and control (Figure 2C). Four of
these miRNAs were up-regulated and seven were down-
regulated in MHFMD and ESHFMD serum samples
compared to the control. miR-671-5p was only ap-
peared in healthy children and MHFMD, and was al-
most undetectable in ESHFMD patients. These data can
provide a valuable repertoire to discover miRNA-based
biomarkers for distinguishing ESHFMD from MHFMD.
qRT-PCR verification of miRNA expression
The most differentially expressed miRNAs miR-671-5p,
miR-16-5p, miR-150-3p, and miR-4281 (results from
microarray analysis) were selected and tested using an in-
dependent cohort of 54 exosome samples (18 ESHFMD,
18 MHFMD, and 18 healthy control) subjected to qRT-
PCR; all the miRNAs passed the quality control. miR-
642a-3p expression was proposed as the normalization
control for exosomal miRNA levels, as the expression level
of miR-642a-3p was almost identical among control,
MHFMD, and ESHFMD groups with almost no differ-
ences in raw Ct values, which was consistent with the
microarray analysis results.
Result indicated that the miR-671-5p, miR-16-5p, and
miR-150-3p expression levels were significantly different
between MHFMD or ESHFMD and the control; more-
over, miR-671-5p was almost undetectable in ESHFMD
in contrast to MHFMD and the control. miR-16-5p,
miR-150-3p, and miR-671-5p showed the same changes
as in the microarray analysis. It obtained that the miR-
16-5p expression in exosome in HFMD serum samples
were found especially higher than that in the normal
children. In contrast, miR-671-5p and miR-150-3p levels
were lower in HFMD than in controls. The serum miR-
16-5p level increased by 5.98 and 10.31 fold in MHFMD
and ESHFMD patients, respectively. Whereas, miR-4281
showed no significant differences between the ESHFMD
group and the control group, or between the ESHFMD
group and MHFMD group (Figure 3).
Evaluation of miR-671-5p, miR-16-5p, and miR-150-3p as
potential diagnostic markers
To determine whether serum miRNA levels in exsome
can be used to distinguish patients with ESHFMD from
those with MHFMD or controls, we established ROC
curves to analyse the difference in miR-671-5p, miR-16-
Figure 1 Characterization of exosomes in serum samples from healthy children and MHFMD and ESHFMD patients by transmission
electron microscopy and western blotting. (A) Morphological characterization by transmission electron microscopy. (B) Molecular
characterization by western blot analysis. Protein extracts prepared from serum (S) or exosomes (Ex) were assessed using antibodies against
exosomal protein markers (TSG101, CD63, CD9, HSP90α and Flotillin).
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5p, and miR-150-3p serum levels between groups. Com-
paring the MHFMD and control groups, the ROC curve
areas for miR-671-5p, miR-16-5p, and miR-150-3p were
found to be 0.79 (95% CI, 0.62–0.91), 0.80 (95% CI,
0.63–0.91), and 0.89 (95% CI, 0.74–0.97), respectively.
The specificity and the sensitivity of each of these miR-
NAs were 72% and 82%, 72% and 83%, and 100% and
78%, for the MHFMD and control groups (Figure 4A),
respectively. These results clearly show that miR-671-5p,
miR-16-5p, and miR-150-3p serum levels can distinguish
MHFMD from healthy controls.
We next compared the serum levels of these miRNAs
between ESHFMD and control groups. The ROC curve
areas of miR-671-5p, miR-16-5p, and miR-150-3p were
1.00 (95% CI, 0.90–1.00), 0.98 (95% CI, 0.86–1.00), and
0.83 (95% CI, 0.67–0.93), respectively. The specificity and
the sensitivity for these miRNAs were 100% and 100%,
100% and 89%, and 100% and 78%, respectively, in the
ESHFMD and control groups (Figure 4B). These results
also demonstrate that the levels of these three miRNAs
(miR-671-5p, miR-16-5p, and miR-150-3p) can distinguish
ESHFMD from healthy controls.
Figure 2 Microarray analysis of HFMD. (A) Scatter plot of miRNA expression determined by miRNA microarray analysis. The expression profile
of 1,887 miRNAs on a log2 scale in HFMD and in the control group is plotted. Red and green dots represent the number of miRNAs that were
significantly (P < 0.05 and 1.5 fold-change cut-off) up-regulated and down-regulated, respectively, in HFMD, and black dots represent a lack of
differential expression. (a) Comparison between normal controls and MHFMD samples, (b) comparison between normal controls and ESHFMD
samples, and (c) comparison between MHFMD and ESHFMD samples. (B) Venn diagram illustrates the overlapping results of the differentially
expressed miRNAs in MHFMD vs. control, ESHFMD vs. control, and MHFMD vs. ESHFMD comparisons. Circles include numbers of up-regulated
or down-regulated human miRNAs of each pair-wise comparison. The 11 miRNAs in the centre of the Venn diagram represent miRNAs that are
differentially expressed in all group comparisons. (C) Heat map analysis of differentially regulated miRNAs among ESHFMD, MHFMD, and control
serum samples according to Venn diagram analysis. Heat map colours represent relative miRNA expression as indicated in the colour key. Red
represents high expression, whereas green represents low expression.
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The comparison of ESHFMD with MHFMD indicated
that miR-671-5p, miR-16-5p, and miR-150-3p levels are
useful markers for discriminating patients with ESHFMD
from those with MHFMD because the ROC curve area of
miR-671-5p, miR-16-5p, and miR-150-3p was 0.82 (95%
CI, 0.65–0.92), 0.76 (95% CI, 0.59–0.88), and 0.76 (95% CI,
0.58–0.88) and the specificity and the sensitivity were 83%
and 78%, 78% and 89%, and 78% and 88% respectively, in
the two groups (Figure 4C). Together, these results
demonstrate that the miR-671-5p, miR-16-5p, and
Figure 3 The box plots depict the relative expression level of four miRNAs (miR-671-5p, miR-150-3p, miR-16-5p and miR-4281)
assessed by qRT-PCR in ESHFMD, MHFMD, and control serum samples. Statistically significant differences were determined using unpaired
Student’s t-test.
Figure 4 Receiver operating characteristic (ROC) curve analysis of miR-671-5p, miR-150-3p, miR-16-5p was performed to discriminate
MHFMD from the control (A), ESHFMD from the control (B), and MHFMD from ESHFMD (C).
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miR-150-3p serum levels can be used to distinguish
MHFMD, ESHFMD, and control samples and reflected
strong separation among these samples.
GO Terms and KEGG pathway annotation of
miRNA targets
GO biology process and KEGG pathway enrichments
were performed by mapping the predicted target genes,
and 20 biology processes for each miRNA and 30, 18,
and 2 KEGG pathways for miR-16-5p, miR-150-3p, and
miR-671-5p were annotated.
The main GO categories annotation showed that devel-
opmental process and regulation of cellular process for
the putative target genes of miR-16-5p and miR-150-3p,
and neurogenesis, regulation of nervous system develop-
ment, neuromuscular process controlling balance and ner-
vous system development for the putative target genes of
miR-150-3p and miR-671-5p were the most significantly
enriched GO terms (Figure 5).
The KEGG pathway enrichment analysis indicated that
the putative targets for these miRNAs were mainly in-
volved in pathways such as those related pathways in neu-
rotrophin signalling pathway, insulin signalling pathway,
TGF-beta signalling pathway, and MAPK signalling path-
way (Figure 5).
Discussion
Early and rapid separation of different disease infection
condition may benefit controlling and prognosis prediction.
Against HFMD, many substantial progresses in understand-
ing the biology and pathogenesis agents continues [6,7,30].
As ESHFMD usually caused majority death, we need to
recognize MHFMD from ESHFMD on the way to reduce
mortality. Early clinical diagnosis, such as disease-associated
miRNAs in exosome could serve as biomarkers, has the
ability for understanding different infection states for
HFMD. It could be also helpful for revealing some intri-
guing aspects regarding the potential function of these miR-
NAs in HFMD.
In this study, we investigated the expression levels of
miRNA profile in exosome from serum samples in
MHFMD and ESHFMD and healthy children. By the two-
step screening and confirmation approach, we identified
3 miRNAs (miR-671-5p, miR-16-5p, and miR-150-3p)
which were significantly different in patients in com-
parison to controls. To evaluate the efficiency of these
miRNAs for diagnosing, ROC curves were constructed
for each miRNA. Expression levels of three miRNAs
(miR-671-5p, miR-16-5p, and miR-150-3p) showed good
ability to efficiently distinguish MHFMD or ESHFMD
from healthy control, with AUC that ranged from 0.79 to
1.00. Combination of three selected exsome miRNAs also
Figure 5 GO category for putative target genes. P < 0.05 was used as a threshold to select significant GO categories and for KEGG pathway
analysis for putative target genes. P < 0.05 was used as a threshold to select significant KEGG pathways; lgP is the negative logarithm of the
P-value. (A) miR-16-5p, (B) miR-150-3p, and (C) miR-671-5p.
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created significantly increased the diagnosis efficiency
to distinguish ESHFMD from MHFMD with AUC of
0.76 to 0.82. Furthermore, the miRNAs (miR-671-5p)
was almost undetectable in ESHFMD when distinguish-
ing it from MHFMD.
Moreover, the miR-16-5p expression in exosome was
found especially higher, and miR-671-5p and miR-150-
3p levels in exosome were particularly lower than that in
healthy children. Recent publications revealed that the
miR-16-5p is up-regulated in various human diseases in-
cluding Alzheimer’s disease and prion disease. It has
been identified as an important intercellular messenger
mediating amyloid precursor protein (APP) protein for-
mation [31]. Up-regulation of miR-16-5p during the
early disease stage and decreased expression with disease
progression was also found in prion disease [31]. It
would therefore be interesting to determine that the
miR-16-5p may have a neuroprotective role. Moreover,
the miR-150-3p levels may be negatively correlated with
plasma TNF-α level in patients [32] and those miR-671-
5p levels may regulate gene expression to promote
tumour growth [33]. From all the related study above, it
may suggest that miR-16-5p, miR-150-3p and miR-671-
5p in exosomes may play an important role in the move-
ment of HFMD.
Further investigate the possible functions of miRNAs
through GO terms and KEGG pathway annotation. The
putative targets for these miRNAs were mainly involved
in such as MAPK signalling pathway related to potential
antiviral mechanisms [34], and the neurotrophin signal-
ling pathway considered to influence the expression of
APP [35]. The predicted target gene of miR-16-5p was
CLU that could clear of beta amyloid peptide, which was
one of the major brain lesions with Alzheimer’s disease
[36-38]. Moreover, the polymorphic genes associated
with Alzheimer’s disease delineate a clear pathway in
young populations [39].
Conclusions
Whereas definitive diagnosis depends on organismspeci-
fic detection results, our data recommended that exso-
mal miRNA profile provide a supplemental biomarker
for differential infection stage at an early stage. They
may share to several signalling pathways, for instance,
the MAPK signalling pathway and neurotrophin signal-
ling pathway, influenced by such as APP formation pro-
tein expression. Further studies, including the functional
exploration of exosomal miRNA profile, will be needed
to make these hypotheses served as the clinical diagnosis
biomarkers.
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